Register Login

IKENA ONCOLOGY, INC. (IMA)

SymbolIMA
NameIKENA ONCOLOGY, INC.
SectorHEALTH CARE
RegionNorth America
IndustryBiotechnology: Biological Products (No Diagnostic Substances)
Address645 SUMMER STREET,SUITE 101, BOSTON, Massachusetts, 02210, United States
Telephone+1 857 273-8343
Fax—
Email—
Websitehttps://www.ikenaoncology.com
IncorporationUNDEFINED
Incorporated On—
Employees—
Fiscal Year—
Public Since—
ExchangesNASDAQ
Auditor—
Audit StatusNOT PROVIDED
Reporting Status—
CIK0001835579
Description

Ikena Oncology Inc is a targeted oncology company developing precision medicines tailored to biomarker-defined patient groups with specific unmet needs. Its lead targeted oncology product candidate, IK-930, is an oral small-molecule inhibitor of the transcriptional enhanced associate domain, or TEAD, transcription factor in the Hippo signaling pathway. The Hippo pathway is genetically altered in approximately 10% of human cancers and is widely accepted as a prevalent driver of cancer pathogenesis and a mediator of poor outcomes for patients.

Additional info from NASDAQ:
ImageneBio is a clinical-stage biotechnology company that boldly imagines a world where patients can be free from the burden of grievous immunological/autoimmune and inflammatory (I&I) diseases. Imagenes purpose is to globally develop new medicines with differentiated profiles that can effectively control and change the course of I&I diseases for affected patients, treat their symptoms, and improve quality of life.

Additional info from NASDAQ:
Ikena Oncology Inc is a targeted oncology company developing precision medicines tailored to biomarker-defined patient groups with specific unmet needs. Its lead targeted oncology product candidate, IK-930, is an oral small-molecule inhibitor of the transcriptional enhanced associate domain, or TEAD, transcription factor in the Hippo signaling pathway. The Hippo pathway is genetically altered in approximately 10% of human cancers and is widely accepted as a prevalent driver of cancer pathogenesis and a mediator of poor outcomes for patients.

2026-08-12 07:04

New Form EFFECT - ImageneBio, Inc. <b>Filed:</b> 2026-08-11 <b>AccNo:</b> 9999999995-26-002625 <b>Size:</b> 1 KB

Read more
2026-08-12 07:04

New Form EFFECT - ImageneBio, Inc. <b>Filed:</b> 2026-08-11 <b>AccNo:</b> 9999999995-26-002624 <b>Size:</b> 1 KB

Read more
2026-08-05 12:00

ImageneBio Reports Second Quarter 2026 Financial Results

Read more
2026-07-28 20:05

Yarema Kristin 🟡 adjusted position in 0 shares (2 derivative) of ImageneBio, Inc. (IMA) Transaction Date: Jul 25, 2026 | Filing ID: 000002

Read more
2026-07-28 17:15

New Form 3 - ImageneBio, Inc. <b>Filed:</b> 2026-07-28 <b>AccNo:</b> 0002064348-26-000002 <b>Size:</b> 10 KB

Read more
2026-07-23 20:25

(99% Neutral) IKENA ONCOLOGY, INC. (IMA) Announces New Board Appointment

Read more
2026-07-23 17:28

New Form 424B3 - ImageneBio, Inc. <b>Filed:</b> 2026-07-23 <b>AccNo:</b> 0001193125-26-314180 <b>Size:</b> 158 KB

Read more
2026-07-21 01:47

Lally Robert B 🔴 sold 3.2K shares of ImageneBio, Inc. (IMA) at $5.50 Transaction Date: Jul 16, 2026 | Filing ID: 000004

Read more
2026-06-29 08:05

New Form 424B3 - ImageneBio, Inc. <b>Filed:</b> 2026-06-29 <b>AccNo:</b> 0001193125-26-286817 <b>Size:</b> 28 KB

Read more
2026-06-18 22:45

Wang Jonathan Jian 🟢 acquired 15.6K shares (1 derivative) of ImageneBio, Inc. (IMA) at $5.45 Transaction Date: Jun 16, 2026 | Filing ID: 000002

Read more